Australian MMR Vaccination Schedule: Two Doses
The Australian immunisation program recommends two doses of MMR vaccine: the first dose at 12 months of age and the second dose at 18 months of age.
Dosing Schedule
The standard Australian schedule differs slightly from the U.S. schedule referenced in the FDA labeling 1. While the FDA label indicates the second dose at 4-6 years 1, Australia administers both doses earlier in childhood to achieve protection sooner.
Specific Timing:
- First dose: 12 months of age
- Second dose: 18 months of age
This accelerated schedule was implemented following Australia's successful Measles Control Campaign (MCC) in 1998, which lowered the age for the second MMR dose from the previous school-entry requirement 2. The campaign involved catch-up vaccination for primary school-aged children and established the current two-dose schedule that has proven highly effective.
Evidence of Effectiveness
Australia's two-dose MMR program has achieved remarkable success:
Measles elimination: The MCC resulted in marked reductions in measles notifications and hospitalizations, with most subsequent outbreaks traced to overseas-acquired infections, suggesting interruption of indigenous transmission 2
Rubella elimination: By 2017, rubella was officially eliminated in Australia, attributed to the national immunization program and enhanced measles activities using MMR vaccines 3
High coverage: Since 2007, MMR coverage among children aged 24-27 months has remained above 90% for both doses 3
Important Caveats
Outbreak Situations
During mumps outbreaks in communal settings (boarding schools, correctional facilities, discrete communities), a third dose of MMR has been offered as an effective public health intervention 4. This additional dose reduced the mumps attack rate from 31.0 to 10.6 per 1000 population in Central Queensland outbreaks 4.
Vulnerable Birth Cohorts
The 1978-1982 birth cohort represents a gap in immunity—they were too old for the 1998 MCC catch-up campaign and too young to have natural mumps infection, resulting in lower seropositivity (92%) and higher mumps incidence in this age group 5.
Waning Immunity Concerns
Recent data suggest potential waning immunity 10-15 years post-vaccination, particularly for rubella in domestic students, though this remains under investigation 6.